NCT05983276 2024-02-08
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
Phase 2 Recruiting
Clinical Trials
3 trialsNCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed